Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-21
2005-06-21
Richter, Johann (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C564S123000, C564S134000, C564S139000, C564S052000, C514S423000, C514S432000, C514S533000, C514S569000, C514S434000, C514S431000, C548S195000, C548S407000, C548S528000, C560S008000, C540S490000
Reexamination Certificate
active
06908934
ABSTRACT:
Compounds of Formula Iand the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of:(a) Formula Ia and(b) Formula Ibare novel LXR agonists and are useful in the treatment of dyslipidemic conditions particularly depressed levels of HDL cholesterol.
REFERENCES:
patent: 6096917 (2000-08-01), Hornback et al.
patent: 6100426 (2000-08-01), Mauldin et al.
patent: 6124494 (2000-09-01), Mauldin et al.
patent: 6180815 (2001-01-01), Mauldin et al.
patent: 0806203 (1997-11-01), None
patent: WO 97/42154 (1997-11-01), None
patent: WO 01/41704 (2001-06-01), None
Young et al., “The ABCs of cholesterol efflux”, Nature Genetics, vol. 22, pp. 316-318 (Aug. 1999).
Bodzioch et al., “The gene encoding ATP-binding cassette transporter I is mutated in Tangier disease”, nature Genetics, vol. 22, pp. 347-351 (Aug. 1999).
Brooks-Wilson et al., “Mutation in ABC1 in Tangier disease and familial high-density lipoprotein deficiency”, Nature Genetics, vol. 22, pp. 336-345 (Aug. 1999).
Rust et al., “Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1”, Nature Genetics, vol. 22, pp. 352-355 (Aug. 1999).
Langmann et al., “Molecular Cloning of athe Human ATP-Binding Cassette Transporter 1 (hABC1): Evidence for Sterol-Dependent Regulation in Macrophanges”, Biochemical and Biophysical Research Communications, vol. 257, pp. 29-33 (1999).
Peet et al., “Cholesterol and Bile Acid Metabolism are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXR alpha”, Cell, vol. 93, pp. 693-704 (May 1998).
Janowski et al., “Structural requirements of ligands for the oxysterol liver X receptors LXR alpha and LXR beta”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 266-271 (Jan. 1999).
Spencer et al., “Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXR alpha”, J. Med. Chem., vol. 44, pp. 886-897 (2001).
Schultz et al., “Role of LXRs in control of lopgenesis”, Genes & Development, vol. 14, pp. 2831-2838 (2000).
Repa et al., “Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers”, Science, vol. 289, pp. 1524-1529 (2000).
Adams Alan D.
Bouffard Aileen
Dropinski James F.
Gutteridge Clare E.
Jones A. Brian
Merck & Co. , Inc.
Nwaonichia Chukwuma
Quagliato Carol S.
Winokur Melvin
LandOfFree
Therapeutic compounds for treating dyslipidemic conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds for treating dyslipidemic conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds for treating dyslipidemic conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493216